Elective colon resection without curative intent in stage IV colon cancer
| Autor: | Richard T. Birkett, MAJ.Mary T. O'Donnell, Nicole M. Saur, Emily Carter Paulson, Joshua I. S. Bleier, Andrew J. Epstein |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Colectomies Multivariate analysis Colorectal cancer medicine.medical_treatment Asymptomatic Gastroenterology Colon resection 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Colectomy Aged Neoplasm Staging Retrospective Studies Aged 80 and over Chemotherapy business.industry Proportional hazards model Liver Neoplasms medicine.disease Survival Rate Oncology Elective Surgical Procedures 030220 oncology & carcinogenesis Colonic Neoplasms Female 030211 gastroenterology & hepatology Surgery medicine.symptom Stage iv business Follow-Up Studies |
| Zdroj: | Surgical Oncology. 28:110-115 |
| ISSN: | 0960-7404 |
| Popis: | Evidence suggests that elective primary colon resection (ePCR) in patients with asymptomatic colon tumors and unresectable metastases is not required and may expose patients to unnecessary operative risk.Stage IV colon cancer patients with liver metastases from 2000 to 2011 were identified with SEER-Medicare data. Liver-based therapy or urgent/emergent colectomies were excluded. Chemotherapy alone was compared to ePCR ± chemotherapy. Univariate and multivariate analyses were used to identify predictors of ePCR. Multivariate Cox regression compared survival.5139 patients were identified. The ePCR rate decreased over time; 84% underwent ePCR in 2000, compared to 52% in 2011 (p 0.001). In multivariate analysis, older patients were more likely to undergo ePCR, as were patients from rural areas (OR 1.65, p 0.001). The odds of PCR in high poverty areas (10%) were almost 25% higher than those in low poverty areas (OR 1.23, p = 0.03). African-Americana were less likely to undergo PCR than Caucasians (OR 0.76, p = 0.01). In multivariate survival analysis, PCR was associated with a significant survival benefit (HR 0.59, p 0.001).Although ePCR is not recommended with unresectable metastases and the rate has decreased significantly, over 50% of patients with untreated hepatic metastases underwent ePCR in 2011. Disparities exist in use of ePCR that are likely multifactorial and deserve further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect